Actively Recruiting
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
Led by M.D. Anderson Cancer Center · Updated on 2026-04-27
15
Participants Needed
2
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
CONDITIONS
Official Title
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant must provide voluntary, written informed consent to participate in this clinical investigation.
- Participant agrees to comply with all study procedures, including all follow-up visits.
- Participant with a Bethesda VI cytology (tumor size <= 1.5 cm, no known regional/distant metastases)
- Participant with a Bethesda V cytology and normal calcitonin levels.
- Ultrasonographic evaluation of tumor to be ablated must show size of less than or equal to 1.5 cm and no extrathyroidal extension or locoregional metastases.
- Participant must have normal complete blood count, blood coagulation profile, and thyroid function test.
- For females of childbearing potential, a negative serum or urine pregnancy test must be obtained at baseline, prior to the procedure.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. This includes all female patients between the onset of menses (as early as 8 years of age) and 55 years unless the patient is postmenopausal, has a history of hysterectomy or bilateral salpingo-oophorectomy, ovarian failure, or history of surgical sterilization.
- Approved methods of birth control include hormonal contraception, intrauterine device, tubal ligation or hysterectomy, subject or partner post vasectomy, implantable or injectable contraceptives, and condoms plus spermicide. Abstinence for the total duration of the trial is acceptable; however, periodic abstinence, rhythm method, and withdrawal method are not acceptable.
- Men must agree to use adequate contraception prior to, during, and for 4 months after study participation.
You will not qualify if you...
- Fine needle aspiration findings suggestive of high-grade malignancy.
- Presence of regional or distant lymph node metastases.
- History of previous neck irradiation.
- Females who are pregnant at time of enrollment.
- Any condition or situation that the investigator believes puts the participant at significant risk, may confound study results, or significantly interfere with participation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sarasota Memorial Hospital
Sarasota, Florida, United States, 34239
Actively Recruiting
2
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
V
Victoria E Banuchi, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here